Business Wire

EHL Awarded for Revamp of Its Flagship Bachelor

26.11.2019 17:11:00 EET | Business Wire | Press release

Share

EHL has been awarded the World Hospitality Awards (WHA) prize for “Innovation in Education”, in recognition of its revamped Bachelor of Science in International Hospitality Management which leverages the full power of the multi-campus education group.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20191126005522/en/

To view this piece of content from mms.businesswire.com, please give your consent at the top of this page.

(Graphic: EHL)

First international campus
Establishing an international presence was a paramount factor in EHL’s plans to enrich its students’ learning and broaden their perspectives. With such clear intent to expand into emerging hospitality markets, EHL Group has been authorized to deliver its Bachelor of Science in International Hospitality Management in Singapore. EHL Campus (Singapore)1 will receive its first cohort in the fall of 2021. In the meantime, the Group plans to deliver short courses on site as early as summer 2020.

“We very much look forward to expanding our connection to the local community and participate in this thriving environment. It is with enthusiasm and conviction that we embark on this new adventure. Our commitment to the local economy will start on-campus and extend throughout the country, as we hope to strengthen our existing ties to the Singaporean hospitality industry”, said EHL Group CEO Michel Rochat.

Candidates can visit: https://singapore.ehl.edu and apply to start their Preparatory Year at EHL Campus Lausanne in September 2020 and then begin their Bachelor course as the first cohort at EHL Campus (Singapore) in September 2021.

1 Bachelor, 2 Pathways, 3 Campuses
The novel organization of EHL’s offering, which the WHA has awarded, is best represented by the new slogan 1 Bachelor, 2 pathways, 3 campuses. 1 degree, representing the world-renowned Bachelor degree which is the foundation of EHL’s global recognition, 2 pathways, as EHL Passugg students who are studying to get a professional diploma are now given the opportunity to extend their studies and work towards a university-level degree. Finally, 3 campuses thanks to the third South-East Asian campus in Singapore, in addition to the Swiss campuses in Lausanne and Passugg.

“EHL has become a truly global education provider and now sets itself further apart by enabling students to aspire for bigger, better things either in Switzerland or abroad. We are proud of being recognized for our pioneering efforts and very much look forward to the new global alliances and partnerships that will stem from our Asian foothold”, concluded Michel Rochat.

1EHL Campus (Singapore) is registered as a private education institution in Singapore under the Private Education Act, Enhanced Registration Framework (ERF), Registration No 201731189N, and has received EduTrust Certification Scheme (Certification number EDU-2-2124, valid from June 14 2019 to June 13 2023).

About EHL Group

www.ehl.edu

To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.

Contact information

EHL Group
Sherif Mamdouh | External Communications Manager
communication@ehl.ch | +41 21 785 10 53

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Positive CHMP Opinion for Zynyz ® (retifanlimab) for First-Line Treatment of Advanced Squamous Cell Carcinoma of the Anal Canal (SCAC)30.1.2026 16:29:00 EET | Press release

Incyte (Nasdaq:INCY) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has issued a positive opinion recommending the approval of Zynyz® (retifanlimab) in combination with carboplatin and paclitaxel (platinum-based chemotherapy) for the first-line treatment of adult patients with metastatic or with inoperable locally recurrent squamous cell carcinoma of the anal canal (SCAC). “Today’s positive CHMP opinion is an important step towards addressing the urgent need for new treatment options for patients in Europe with advanced SCAC, a disease which has seen limited innovation for decades,” said Lee Heeson, Executive Vice President and Head of Incyte International. “If approved, Zynyz in combination with platinum-based chemotherapy has the potential to become a new standard-of-care for patients living with this rare and difficult-to-treat cancer.” The positive CHMP opinion was based on data from the Phase 3 POD1UM-303/Inter

Mediawan to Acquire The North Road Company, Creating a New Global Independent Content Platform30.1.2026 14:32:00 EET | Press release

Mediawan, the leading independent European studio led by Pierre-Antoine Capton, co-founded by Capton, Xavier Niel and Matthieu Pigasse, today announced the signing of an agreement to acquire The North Road Company (“North Road”), the preeminent independent U.S.-based studio founded by Peter Chernin. The combination creates one of the world’s largest independent studios with major creative hubs in the five continents and capabilities spanning all genres, formats and audiences. Together, Mediawan and North Road will have a stronger ability to accelerate the development of powerful IP, foster fresh creative synergies through format adaptations and co-production opportunities, and deliver ever greater value to viewers, talent and partners worldwide. The acquisition brings together two of the most dynamic independent studios in the sector with world-class creative talent, premium IP, and the scale to deliver content at the highest level. In an industry undergoing significant consolidation,

BrightSign Powers Intelligent Signage Experiences at ISE 202630.1.2026 10:00:00 EET | Press release

With more industries embracing the power of visual storytelling, BrightSign, the provider of the most advanced, capable, and trusted digital media players and operating system, will showcase the latest developments in digital signage technology at ISE 2026 in Barcelona, Spain from February 3-6, 2026. BrightSign’s latest innovations come to life at booth #4S-150 through interactive real-world demos featuring retail, QSR, transportation, and corporate use cases. Visitors can test new AI-powered object detection capabilities of BrightSign players, allowing them to pick up an object and see the content on the screen respond immediately. Booth activations will be powered by BrightSign’s reliable platform including bsn.Control, BrightSignOS™, brightAuthor connected, and its global partner ecosystem. “In today’s immersive, personalized and visual world, the stakes have never been higher for powerful, secure, reliable, and intelligent digital signage,” said Steve Durkee, chief executive office

Candela Ushers in a New Era of Aesthetic Innovation at IMCAS Paris With the Launch of the Glacē™ System30.1.2026 09:30:00 EET | Press release

Candela, a global leader in energy-based aesthetic technologies, today announced the European launch of the Glacē™ System, a facial treatment platform that signals a bold new chapter for the company and the future of aesthetic medicine. In addition to the launch of the Glacē System, Candela will also showcase its Matrix system for radiofrequency-based skin renewal and its iconic Vbeam® Pro vascular treatment platform at IMCAS 2026. Both Matrix and VBeam Pro platforms are currently available in select EMEA markets and are expected to be comprehensively launched shortly, further strengthening Candela’s leadership in the energy-based device market. Unveiled at the IMCAS World Congress 2026, these launches underscore Candela’s continued commitment to delivering innovative, science-backed treatment solutions for high-demand patient needs. Candela leads the industry in clinical efficacy and safety, supported by one of the largest bodies of published clinical data backed by decades of clinica

Merz Therapeutics Appoints Dan Staner as President, Region Europe30.1.2026 09:00:00 EET | Press release

Merz Therapeutics today announced the appointment of Dan Staner as President, Region Europe, effective February 1, 2026. In this role, Dan will oversee the company’s European business and drive regional growth. Dan will report directly to Merz Therapeutics Chief Executive Officer, Stefan König, and will join the Therapeutics Executive Team. His appointment reflects the company’s continued commitment to strengthening its leadership capabilities and accelerating its growth strategy across key European markets.​ “Dan brings a strong track record of building and scaling biopharmaceutical businesses across Europe,” said Stefan König, CEO of Merz Therapeutics. “His deep commercial, strategic, and regional leadership experience will be instrumental in advancing our growth ambitions, expanding patient access to our therapies, and further strengthening our presence in Europe. We are very pleased to welcome Dan to Merz Therapeutics.”​ Throughout his career, Dan has held senior leadership roles i

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye